Human liver microsomal metabolism of paclitaxel and drug interactions

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 23, Issue 3, 1998, Pages 417-424

  Desai, Pankaj B ^a   Duan, John Z ^a,c   Zhu, Y W ^a   Kouzi, S ^b  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UNIVERSITY OF LOUISIANA AT MONROE   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Hepatic metabolism drug interactions; Human microsomes; Paclitaxel; R verapamil; Tamoxifen

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOSPORIN A; CYTOCHROME P450 ISOENZYME; DOXORUBICIN; DRUG METABOLITE; ETOPOSIDE; KETOCONAZOLE; PACLITAXEL; QUERCETIN; TAMOXIFEN; VERAPAMIL;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; HUMAN; HUMAN TISSUE; LIVER MICROSOME METABOLISM;

EID: 0031795319     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03192303     Document Type: Article

References (31)

1. Schiff P.B., Fant J., Horwitz S. (1979) : Promotion of microtubule assembly in vitro by taxol. Nature, 277, 665-667.
2. Rowinsky E.K., Gilbert M.R., McGuire W.P. et al. (1991) : Sequences of taxol and cisplatin: a phase I and pharmacologic studies. J. Clin. Oncol., 9, 1692-1703.
3. Sledge G.W., Robert N., Sparano J.A. et al. (1994) : Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: The Eastern Cooperative Oncology Group experience. Semin. Oncol., 21 (suppl. 8), 15-18.
4. Hortobagyi G.N. (1997) : Paclitaxel-based combination chemotherapy for breast cancer. Oncology, XX, 29-37.
5. Cresteil T., Monsarrat B., Alvinerie P., Tréluyer J.M.T, Vierira I., Wright M. (1994) : Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res., 54, 386-392.
6. Kumar G.N., Walle U.K., Walle T. (1994) : Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation. J. Pharmacol. Exp. Ther., 268, 1160-1165.
7. Harris J.W., Rahman A., Kim B-R., Guengerich P.P., Collins J.M. (1994) : Metabolism of Taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res., 54, 4026-4035.
8. Rahman A., Korekwa K.R., Grogan J., Gonzalez F.J., Harris J.W. (1994) : Selective biotransformation of taxol to 6α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res., 54, 5543-5546.
9. Walle T., Walle U.W., Kumar G.N., Bhalla K.N. (1995) : Taxol metabolism and disposition in cancer patients. Drug Metab. Dispos., 23, 506-512.
10. Sonnichsen D.S., Liu Q., Schuetz E.G., Schuetz J.D., Pappo A., Relling M.V. (1995) : Variability in human cytochrome P450 paclitaxel metabolism. J. Pharmacol. Exp. Ther., 275, 566-575.
11. Sonnichsen D.S, Hurwitz C.A., Pratt C.B., Shuster J.J., Relling M.V. (1994) : Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J. Clin. Oncol. 12, 532-538.
12. Beijnen J.H., Huizing M.T., ten Bokkel W.W., et.al. (1994) : Bioanalysis, pharmacokinetics and pharmacodynamics of the novel anti-cancer drug paclitaxel (Taxol). Semin. Oncol., 21 (suppl 8), 53-62.
13. Berg S.L., Tolcher A., O'Shaughnessy J.A. et al. (1995) : Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J. Clin. Oncol., 13, 2039-2042.
14. Huizing M.T., Sparreboom A., Rosing H., van Tellingen O., Pinedo H.M., Beijnen J.H. (1995) : Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography. J. Chromatogr. B: Biomed Appl., 674, 261-268.
15. Kumar G., Ray S., Walle T. et.al. (1995) : Comparative in vitro cytotoxic effects of taxol and its major human metabolite 6α-hydroxypaclitaxel. Cancer Chemother. Pharmacol., 36, 129-135.
16. Juranka P.F., Zastawny R.I., Ling V. (1989) : P-glycoprotein: multidrug resistance and a superfamily of membrane-associated transport proteins. FASEB J., 3: 2583-2592.
17. Horwitz S.B., Lothstein L., Manfredi J.J. et al. (1986) : Taxol: Mechanisms of action and resistance. Ann. N.Y. Acad. Sci., 466, 733-744.
18. Lum B.L., Fisher G.A., Brophy N.A. et. al. (1993) : Clinical trials of modulators of multidrug resistance: pharmacokinetic and pharmacodynamic consideration. Cancer, 72, 3502-3514.
19. Stuart N.S.A., Philip P., Harris A.L. et.al. (1992) : High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in P-glycoprotein expressing cell lines. Br. J. Cancer, 66, 833-839.
20. Buckley M.M-T., Goa K.L. Tamoxifen. (1989) : A re-appraisal of its pharmacodynamics and pharmacokinetic properties, and therapeutic use. Drugs, 37, 451-490.
21. Royer I., Monsarrat B., Sonnier M., Wright M., Cresteil T. (1996) : Metabolism of docetaxel by human cytochrome P450: interactions with paclitaxel and other anti-neoplastic agents. Cancer Res., 56, 58-65.
22. Lum B.L., Kaubisch S., Yahanda A.M. et al. (1992) : Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporin in a phase I trial to modulate multidrug resistance. J. Clin. Oncol., 10, 1635-1642.
23. Mani C., Gelboin H.V., Park S.S., Pearce R., Parkinson A., Kupfe D. (1993) ; Metabolism of the antimammary cancer anti-estrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab. Dispos., 21, 645-656.
24. Kroemer H.K., Gautier J.C., Beaune P., Henderson C., Wolf C.R., Eichelbaum M. (1993) : Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch. Pharmacol., 348, 332-337.
25. Lemoine A., Azoulay D., Gries J.M. et.al. (1993) : Relationship between graft cytochrome P-450 3A content and early morbidity after liver transplantation. Transplantation. 56, 1410-1414.
26. Leblanc G.A., Sundseth S.S., Weber G.F., Waxman D.J. (1992) : Platinum anti-cancer drugs modulate P450 mRNA levels and differentially alter hepatic drug and steroid metabolism in male and female rats. Cancer Res., 52, 540-547.
27. Relling M.V., Nemec J., Schuetz E.G., Schuetz J.D., Gonzalez F.J., Korzekwa K.R. (1994) : O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol. Pharmacol., 45, 352-358.
28. Kivisko K.T., Kroemer H.K., Eichelbaum M. (1995) : The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implication for drug interactions. Br. J. Clin. Pharmacol., 40, 523-530.
29. Lien E.A., Solheim E., Ueland P.M. (1991) : Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res., 51, 4837-4844.
30. Hamann S.R., Todd G.R., McAllister R.G. (1983) : The pharmacology of verapamil. V. Tissue distribution of verapamil and norverapamil in rat and dog. Pharmacology, 27, 1-8.
31. 3H]-paclitaxel in rats: a quantitative autoradiographic study. Cancer Chemother. Pharmacol., 37, 173-178.